In 2019, 212,000 deaths due to smoking reported in Japan [1]. Smoking is strongly linked to mortality and various conditions, including cancer and cardiovascular disease (CVD). However, it is a modifiable risk factor—one that can be eliminated by quitting.
Smoking acutely elevates blood pressure (BP) and heart rate (HR) [2], and habitual smoking is associated with the development of hypertension [3,4,5]. Additionally, smoking can attenuate the effect of medications in patients with hypertension and has been linked with masked hypertension [6, 7]. Both smoking and hypertension are also recognized as risk factors for severe COVID-19, a disease that emerged in late 2019 [8, 9].
In recent years, there has been a surge in the use of new tobacco products, which are not harmless. Studies indicate that they can cause respiratory, cardiac, and vascular damage, elevate BP and HR [10,11,12,13]; and increase the risk of severe COVID-19 [14, 15].
The Health Promotion Act has also been revised to combat the health hazards associated with secondhand smoke, emphasizing the need to prevent “unwanted passive smoking”. The updated legislation was fully implemented on April 1, 2020.
In light of these considerations, we, the members of the Japanese Society of Hypertension (JSH), declare our commitment to the following practices:
-
1.
We, the members ourselves, pledge to abstain from all tobacco products*, including new tobacco products (mainly heated tobacco products and electronic non-nicotine/nicotine delivery system). * ”Tobacco products” hereafter.
-
2.
We will actively encourage smokers to quit and pledge to offer full support and positive guidance. Additionally, we will also provide advice on diet, exercise, and nicotine replacement therapy to mitigate associated health issues, such as hypertension and diabetes, that may arise from weight gain during the process of smoking cessation.
-
3.
We will encourage non-smokers to maintain smoke-free** lifestyle and take steps to avoid exposure to passive smoke. ** Tobacco product use prohibited
-
4.
The grounds of the JSH conference venue will be designated as a smoke-free zone.
-
5.
We will support and promote research on the health risks associated with tobacco products use and the benefits of quitting.
-
6.
In cooperation with relevant academic societies and organizations, we will undertake initiatives to promote smoking cessation and foster a social environment free from passive smoking.
-
7.
As in the past, we will not accept donations from tobacco companies or affiliated institutions. In addition, we will refrain from publishing articles in Hypertension Research submitted by individuals or organizations that receive support from tobacco companies.
Based on this declaration, we, the JSH members, will continue to promote smoking cessation and contribute towards hypertension prevention and management, and CVD prevention.
In preparation for this declaration, the results of a survey of JSH members conducted from September to December 2023 are attached as Supplement Data.
References
GBD 2019 Risk Factors Collaborators. Global burden of 87 risk factors in 204 countries and territories, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019. (page 6724 in Supplement 3) Lancet. 2020;396:1223–49.
Rhee MY, Na SH, Kim YK, Lee MM, Kim H. Acute effects of cigarette smoking on arterial stiffness and blood pressure in male smokers with hypertension. Am J Hypertens. 2007;20:637–41.
Levy RV, Brathwaite KE, Sarathy H, Reidy K, Kaskel F, Melamed M. Analysis of active and passive tobacco exposures and blood pressure in US children and adolescents. JAMA Netw Open. 2021;4:e2037936.
Herath P, Wimalasekera S, Amalasekara T, Fernando M, Turale S. Effect of cigarette smoking on smoking biomarkers, blood pressure and blood lipid levels among Sri Lankan male smokers. Postgrad Med J. 2022;98:848–54.
Park H, Jeong H, Yim HW, Bae S. Associations of active and passive tobacco exposure with elevated blood pressure in Korean adolescents. Epidemiol Health. 2024;46:e2024028.
Leone A. Does Smoking Act as a Friend or Enemy of Blood Pressure? Let Release Pandora’s Box. Cardiol Res Pract. 2011; 264894. https://doi.org/10.4061/2011/264894.
Zhang D-Y, Fuang JF, Kang YY, Dou Y, Su YL, Zang LJ, et al. The prevalence of masked hypertension in relation to cigarette smoking in a Chinese male population. J Hypertens. 2020;38:1056–63.
CDC COVID-19 Science Briefs [Internet]: Evidence used to update the list of underlying medical conditions associated with higher risk of severe COVID-19. 9, 2023.
Terada M, Ohtsu H, Saito S, Hayakawa K, Tsuzuki S, Asai Y, et al. Risk factors for severity on admission and the disease progression during hospitalisation in a large cohort of patients with COVID-19 in Japan. BMJ Open. 2021;11:e047007.
Znyk M, Jurewicz J, Kaleta D. Exposure to heated tobacco products and adverse health effects, a systematic review. Int J Environ Res Public Health. 2021;18:6651.
Fried ND, Gardner JD. Heat-not-burn tobacco products: an emerging threat to cardiovascular health. Am J Physiol Heart Circ Physiol. 2020;319:H1234–9.
Neczypor EW, Mears MJ, Ghosh A, Sassano MF, Gumina RJ, Wold LE, et al. E-cigarettes and cardiopulmonary health: review for clinicians. Circulation. 2022;145:219–32.
Larue F, Tasbih T, Ribeiro PAB, Lavoie KL, Dolan E, Bacon SL, et al. Immediate physiological effects of acute electronic cigarette use in humans: A systematic review and meta-analysis. Respir Med. 2021;190:106684.
Nishimura M, Asai K, Tabuchi T, Toyokura E, Kawai T, Miyamoto A, et al. Association of combustible cigarettes and heated tobacco products use with SARS-CoV-2 infection and severe COVID-19 in Japan: a JASTIS 2022 cross-sectional study. Sci Rep. 2023;13:1120.
Singhal S, Degano C, Berenbaum E, Keller-Olaman S. Does vaping increase the risk of COVID-19 transmission and make individuals who vape susceptible to infection and prone to severe illness? A review. J Can Dent Assoc. 2022;88:m1.
JSH Smoke-Free Promotion Committee members
Kimika Arakawa1, Yuichi Akasaki2, Ako Fukami3, Satoko Sakata4,5, Ken Sugimoto6, Hirochika Ryuno7, Mai Kabayama8, Mitsuru Ohishi2
Author information
Authors and Affiliations
Consortia
Corresponding author
Ethics declarations
Conflict of interest
The authors declare no competing interests.
Additional information
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
JSH Former President, Chairman of the 46th Annual Meeting of the Japanese Society of Hypertension; Koichi Node.
Supplementary information
Rights and permissions
About this article
Cite this article
Arakawa, K., Akasaki, Y., Fukami, A. et al. JSH2024 smoke-free declaration “Stop All Tobacco Products”. Hypertens Res 48, 449–450 (2025). https://doi.org/10.1038/s41440-024-02073-z
Received:
Revised:
Accepted:
Published:
Version of record:
Issue date:
DOI: https://doi.org/10.1038/s41440-024-02073-z